Search Page

1

Cite

Share

Hip disease in ankylosing spondylitis.

Vander Cruyssen B, Vastesaeger N, Collantes-Estévez E. Vander Cruyssen B, et al. Among authors: vastesaeger n. Curr Opin Rheumatol. 2013 Jul;25(4):448-54. doi: 10.1097/BOR.0b013e3283620e04. Curr Opin Rheumatol. 2013. PMID: 23689637 Review.

Cite

Share

2

Cite

Share

A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis.

Vastesaeger N, Xu S, Aletaha D, St Clair EW, Smolen JS. Vastesaeger N, et al. Rheumatology (Oxford). 2009 Sep;48(9):1114-21. doi: 10.1093/rheumatology/kep155. Epub 2009 Jul 9. Rheumatology (Oxford). 2009. PMID: 19589891 Review.

Cite

Share

3

Cite

Share

An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases.

Vanier A, Smolen JS, Allaart CF, Van Vollenhoven R, Verschueren P, Vastesaeger N, Saevarsdottir S, Visser K, Aletaha D, Combe B, Fautrel B. Vanier A, et al. Among authors: vastesaeger n. Rheumatology (Oxford). 2020 Aug 1;59(8):1842-1852. doi: 10.1093/rheumatology/kez542. Rheumatology (Oxford). 2020. PMID: 31722413

Cite

Share

4

Cite

Share

Predicting the outcome of ankylosing spondylitis therapy.

Vastesaeger N, van der Heijde D, Inman RD, Wang Y, Deodhar A, Hsu B, Rahman MU, Dijkmans B, Geusens P, Vander Cruyssen B, Collantes E, Sieper J, Braun J. Vastesaeger N, et al. Ann Rheum Dis. 2011 Jun;70(6):973-81. doi: 10.1136/ard.2010.147744. Epub 2011 Mar 14. Ann Rheum Dis. 2011. PMID: 21402563 Free PMC article. Clinical Trial.

Cite

Share

5

Cite

Share

Clinical and quality of life improvements with golimumab or infliximab in a real-life ankylosing spondylitis population: the QUO-VADIS study.

Van den Bosch F, Flipo RM, Braun J, Vastesaeger N, Kachroo S, Govoni M. Van den Bosch F, et al. Among authors: vastesaeger n. Clin Exp Rheumatol. 2019 Mar-Apr;37(2):199-207. Epub 2018 Jul 19. Clin Exp Rheumatol. 2019. PMID: 30148434

Cite

Share

6

Cite

Share

Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial.

Durez P, Pavelka K, Lazaro MA, Garcia-Kutzbach A, Moots RJ, Amital H, Govoni M, Vastesaeger N. Durez P, et al. Among authors: vastesaeger n. Clin Rheumatol. 2018 May;37(5):1417-1420. doi: 10.1007/s10067-018-4074-6. Epub 2018 Apr 2. Clin Rheumatol. 2018. PMID: 29611083 Clinical Trial.

Cite

Share

7

Cite

Share

Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial.

Durez P, Pavelka K, Lazaro MA, Garcia-Kutzbach A, Moots RJ, Amital H, Govoni M, Vastesaeger N. Durez P, et al. Among authors: vastesaeger n. Clin Rheumatol. 2018 Jul;37(7):2017-2018. doi: 10.1007/s10067-018-4131-1. Clin Rheumatol. 2018. PMID: 29752584

Cite

Share

8

Cite

Share

Association of Inflammatory Bowel Disease and Acute Anterior Uveitis, but Not Psoriasis, With Disease Duration in Patients With Axial Spondyloarthritis: Results From Two Belgian Nationwide Axial Spondyloarthritis Cohorts.

Varkas G, Vastesaeger N, Cypers H, Colman R, Renson T, Praet LV, Carron P, Raeman F, Devinck M, Gyselbrecht L, Corluy L, Piette Y, Lenaerts J, Thevissen K, Vanneuville B, Bosch FVD, Elewaut D. Varkas G, et al. Among authors: vastesaeger n. Arthritis Rheumatol. 2018 Oct;70(10):1588-1596. doi: 10.1002/art.40551. Arthritis Rheumatol. 2018. PMID: 29740978

Cite

Share

9

Cite

Share

Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohort.

Claudepierre P, Van den Bosch F, Sarzi-Puttini P, Vastesaeger N, Govoni M, Kachroo S. Claudepierre P, et al. Among authors: vastesaeger n. Int J Rheum Dis. 2019 Jun;22(6):995-1001. doi: 10.1111/1756-185X.13526. Epub 2019 Apr 15. Int J Rheum Dis. 2019. PMID: 30989813

Cite

Share

10

Cite

Share

Effectiveness and safety of infliximab in two cases of severe chondrocalcinosis: nine years of follow-up.

Bruges-Armas J, Bettencourt BF, Couto AR, Lima M, Rodrigues AM, Vastesaeger N, Brown MA. Bruges-Armas J, et al. Among authors: vastesaeger n. Case Rep Rheumatol. 2014;2014:536856. doi: 10.1155/2014/536856. Epub 2014 Nov 11. Case Rep Rheumatol. 2014. PMID: 25436167 Free PMC article.

Cite

Share